Divi's Lab

Divi's Lab sinks 13%, hits 29-mth low as Q3 profit falls more than expected

In Q3FY23, Divi's Lab reported a 66 per cent year-on-year decline in its consolidated net profit at Rs 306.80 crore, on higher than expected in fall in revenue

Sensex ends subdued day 235 pts up, Nifty swings above 18,200; SBI leaps 3%

CLOSING BELL: The Nifty PSU Bank index sharply outperformed other indices as it gained 4.5 per cent

Divi's Lab Q4 net up 78% at Rs 895 cr, revenue rises 41% to Rs 2,518 cr

Divi's Laboratories on Monday said its consolidated net profit increased by 78 per cent to Rs 895 crore in the quarter ended on March 31, 2022.

Divi's Labs second quarter net profit rises 17% to Rs 606 crore

The company had posted a net profit of Rs 519.59 crore for the corresponding period of the previous fiscal

MARKET WRAP: Sensex up 288 pts, ends above 39K; mid, small-caps outperform

All that happened in the markets today

Divi's Lab surges 15%, hits fresh 52-week high on robust Q1 earnings

The company reported a net profit of Rs 492.06 crore for the quarter

Sebi fines Divi's Laboratories CFO L Kishore Babu for insider trading

It said Divi's had made an announcement on July 10, 2017, during market hours that the US FDA would lift import alert 99-32 on the company's unit-II at Visakhapatnam

Divi's Labs cash in on bullish sentiment, strong growth prospects

The second largest pharma player by market value is also expanding capacities to push earnings

Divi's stock: Pricing pressure for drug makers can lead to more outsourcing

Analysts at Motilal Oswal Securities expect Divi's earnings before interest, tax, depreciation and amortisation (Ebitda) margin to improve by 400 basis points to 36 per cent